source
- Talawar Therapeutics merges with JATT II Acquisition to list on Nasdaq as AstraZeneca reports Phase 3 success in pediatric bone diseaseTalawar Therapeutics announced a combination with blank‑check company JATT II Acquisition Corp, a deal that will place Talawar on the Nasdaq exchange. The SPAC transaction gives Talawar public‑mar…
- Chinese partnerships are becoming the pharma industry's new tax inversion strategyThe article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…